← Leaderboards
Md Jashim Uddin
Vanderbilt University
$728,003
Attributed
$3,035,458
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $673.2K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,035,458 · 1
By mechanism
R01$3,035,458 · 1
Top collaborators
- Rebecca Sara Cook7 shared
- Craig Lewis Duvall7 shared
- Kasey C Vickers7 shared
- Dana M Brantley-Sieders1 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Rebecca Sara Cook$4,266,124
- John Tanner Wilson$7,006,172
- Thomas A Werfel$1,074,749
- Benjamin Christian Hacker$78,323
- Alexander Kwiatkowski$148,112
Others in their field
Other Emerging Leaders on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
- Yunda Huang · Fred Hutchinson Cancer Center$53,780,853
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Kathleen Maletic Neuzil · Emory University$27,014,427
Research focus
Drug KineticsGenesConsultationsDrug Delivery SystemsAllograftingFaceClinical OncologyBindingCookingDesignBiomedical EngineeringAutomobile DrivingBasic ScienceBreast Cancer PatientBenchmarkingAlbuminsCancer Clinical TrialCancer SubtypesCell MembraneApoptoticChemical SynthesisBiologicalChemotherapyGenome
Grant awards (7)
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$550,518
R01 · FY2025 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$522,993
R01 · FY2024 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$555,637
R01 · FY2023 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$117,567
R01 · FY2023 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$553,948
R01 · FY2022 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$117,567
R01 · FY2022 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$617,228
R01 · FY2021 · CA